COMPUGEN LTD
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 5.2
- Dividend yield
- –
About Compugen
Biological Products, (No Diagnostic Substances), SIC 2836
Compugen Ltd. is a clinical-stage biotechnology company that discovers and develops therapeutic candidates for cancer immunotherapy and immuno-oncology. The company operates in a single operating segment and utilizes an artificial intelligence and machine learning discovery platform called Unigen to identify novel drug targets. Its primary therapeutic pipeline programs include COM701, COM902, GS-0321, and rilvegostomig, a bispecific antibody developed with a partner. Compugen collaborates with and licenses its therapeutic assets to major pharmaceutical and biotechnology companies, including AstraZeneca and Gilead Sciences.
The company maintains its executive headquarters in Holon, Israel, and conducts business operations through its Israeli parent entity and its wholly owned subsidiary, Compugen USA, Inc. Compugen carries out research, development, and partnering activities with operations and commercial counterparties spanning Israel, the United States, and the United Kingdom. Its operational footprint includes specialized research laboratory facilities, computer equipment, and office infrastructure supporting its internal scientific staff and management team.
Summary of the business section of Compugen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- COMPUGEN LTD
- Headquarters
- Holon, L3
- Address
- 26 Harokmim Street, Building D 5885849
- Phone
- 011-972-3-765-8585
- Employees
- 16, Dec 31, 2014
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- KOST FORER GABBAY & KASIERER, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- CGEN
- Exchange
- Nasdaq
- Shares outstanding
- 95M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1119774
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eran Ophir | President and CEO, Director | 11,375 |
| Pierre Ferre | Chief Operating Officer | – |
| Michelle Mahler | Chief Medical Officer | 36,625 |
| Zurit Levine | SVP, Business Development | 47,375 |
| David Silberman | Chief Financial Officer | 55,000 |
| Russo Sharon Kredo | SVP, Research & Discovery | 37,500 |
| Anat Cohen-Dayag | Director | 108,622 |
| Eran Perry | Director | 17,500 |
| Mathias Hukkelhoven | Director | 17,500 |
| Gilead Halevy | Director | 18,907 |
| Savitzky Kinneret Livnat | Director | 20,850 |
| Sanford S. Zweifach | Director | 20,180 |
| Michele Holcomb | Director | 15,000 |